Pancreatic Cancer Research

ResearcherHarold C. Simmons Comprehensive Cancer CenterActive in the last 2 years

Adam Charles Yopp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5887-5315; OpenAlex author ID A5085283718. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper

Papers 11

  1. Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-3582↗
  2. Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.022↗
  3. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-023-14805-5↗
  4. Factors associated with failure to operate and its impact on survival in early-stage pancreatic cancer. Co-author DOI 10.1002/jso.27357↗
  5. Implications of the interaction between travel burden and area deprivation for patients with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2023.06.013↗
  6. Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? Co-author DOI 10.1245/s10434-023-13308-7↗
  7. Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. Co-author DOI 10.1245/s10434-019-08096-y↗
  8. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2018.7068↗
  9. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Co-author DOI 10.1200/jco.2016.68.5081↗
  10. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Co-author DOI 10.1038/ncomms7744↗
  11. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcin… Co-author DOI 10.1097/sla.0b013e318214bcb4↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Patricio Marcelo Polanco · 9 shared papers, 2017–2025 · strength 1.37
  2. Herbert J. Zeh · 7 shared papers, 2020–2025 · strength 1.22
  3. Matthew R. Porembka · 7 shared papers, 2017–2025 · strength 0.99
  4. John C. Mansour · 7 shared papers, 2015–2025 · strength 0.85
  5. Sam C. Wang · 6 shared papers, 2017–2024 · strength 0.81
  6. Gilbert Zvikomborero Murimwa · 3 shared papers, 2023 · strength 0.56
  7. Ahmed M. Elamir · 2 shared papers, 2024–2025 · strength 0.34
  8. Todd Anthony Aguilera · 2 shared papers, 2024–2025 · strength 0.34
  9. Megan Wachsmann · 2 shared papers, 2024–2025 · strength 0.34
  10. Caitlin A. Hester · 2 shared papers, 2020–2023 · strength 0.28
  11. Amr I. Al Abbas · 1 shared paper, 2024 · strength 0.21
  12. Emile Farah · 1 shared paper, 2024 · strength 0.21
  13. Nina Niu Sanford · 1 shared paper, 2025 · strength 0.18
  14. Syed Mohammad Ali Kazmi · 1 shared paper, 2025 · strength 0.18
  15. Zhikai Chi · 1 shared paper, 2025 · strength 0.18
  16. Muhammad Shaalan Beg · 1 shared paper, 2025 · strength 0.18
  17. Peter Q. Leung · 1 shared paper, 2025 · strength 0.18
  18. Salwan S. Al Mutar · 1 shared paper, 2025 · strength 0.18
  19. Giovanni Luigi Capretti · 1 shared paper, 2024 · strength 0.16
  20. Iván Pedrosa · 1 shared paper, 2024 · strength 0.16
  21. Alessandro Zerbi · 1 shared paper, 2024 · strength 0.16
  22. Ravi Kiran Kaza · 1 shared paper, 2024 · strength 0.16
  23. Matteo Ligorio · 1 shared paper, 2024 · strength 0.16
  24. Kai Wang · 1 shared paper, 2024 · strength 0.16
  25. Ali A. Mokdad · 2 shared papers, 2017–2018 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.